Ignite Creation Date:
2024-05-06 @ 1:44 PM
Last Modification Date:
2024-10-26 @ 1:19 PM
Study NCT ID:
NCT04111809
Status:
UNKNOWN
Last Update Posted:
2022-11-01
First Post:
2019-09-04
Brief Title:
Study of 4 Bone Turnover Markers in Patients With Multiple Myeloma Treated With Intravenous Bisphosphonate in Routine Care
Sponsor:
Assistance Publique - Hôpitaux de Paris
Organization:
Assistance Publique - Hôpitaux de Paris
Study Overview
Official Title:
Assessment of 4 Bone Turnover Markers C-terminal Telopeptides of Type I Collagene CTX Amino-terminal Telopeptide of Type 1 Collagen NTX Dickkopf-1 DKK-1 and Sclerostin SOST in Multiple Myeloma Patients Treated With Intravenous Bisphosphonate
Status:
UNKNOWN
Status Verified Date:
2022-10
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
AMBROBiMM
Brief Summary:
The aim of this study is looking at the Kinetics of bone turnover markers C-terminal telopeptides of type I collagene CTX amino-terminal telopeptide of type 1 collagen NTX Dickkopf-1 DKK-1 and Sclerostin SOST in serum and urine until 12 months in Patients with Multiple Myeloma Treated With intravenous bisphosphonates in routine care
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None